COVID-19

iRemedy announced that in association with the Company’s effort to procure and deliver one billion FDA-approved hypodermic needles and syringes in support of COVID-19 vaccination programs worldwide, over 130 million units have been delivered to customers since announcing its program in November 2020.

UVC PureLight 360 Test results from a leading independent international laboratory confirm that the patent-pending 320W UVC Induction/LED prototype from Miami-based UVC PureLight 360 LLC inactivates more than 99.9% of COVID-19 in a 16' X 16' room in as little as 3.5 minutes.

SARS-Hunter gives the possibility to hospitals to isolate the antibodies from plasma to be given as therapy and increases the chances of success of treatment, while reducing the side effects of plasma therapy given today.

Yates Enterprises founder and CEO, William Yates, MD, anticipated COVID-19 would become a serious public health issue in the U.S. early on.

It has already launched its new Respiratory Infectious Disease Health Check to existing MCMS customers, and it is now launching a new COVID-19 Virtual Care Evaluation and Monitoring solution available to U.S. health systems, health plans and employers. 

The ixlayer COVID-19 Clinical Test Platform already encompassing the security components that are complex and time-consuming to deliver, has been adapted for COVID-19 specific content and user flows, allowing physicians/health systems, organizations, and university groups to quickly connect with partnering labs to deliver COVID-19 clinical testing.

Physician-scientists at the University of California, San Diego (UCSD) are the first to evaluate a new covid-19 diagnostic test system designed by Irvine, CA-based Fluxergy, that holds promise for identifying the SARS-CoV-2 virus (also known as the novel coronavirus) in as little as 45 minutes and typically within one hour.